华润医药(03320)：昆药集团上半年归母净利约1.98亿元，同比减少26.88%

Core Viewpoint - China Resources Pharmaceutical (03320) reported a decline in revenue and net profit for Kunming Pharmaceutical Group in the first half of 2025, indicating potential challenges in the company's financial performance [1] Financial Performance - Total revenue for the first half of 2025 was approximately 3.351 billion yuan, representing a year-on-year decrease of 11.68% [1] - Net profit attributable to shareholders was about 198 million yuan, down 26.88% year-on-year [1] - Basic earnings per share were reported at 0.26 yuan [1]